ArticleChemMedChem2026
Investigating the Inhibitory Properties of Diazo and Pyrazole-Carboxamide-Linked Benzenesulfonamides Against Carbonic Anhydrase Isoforms I, II, IX, and XII.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design,ACS omega · 2026Article
- Recent Advances in Pyrazole-Based Cholinesterase Inhibitors: Medicinal Chemistry Perspectives from 2020 to 2025.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A novel library of diazo and pyrazole-carboxamide-linked molecules containing the sulfonamide pharmacophore was developed and synthesized, yielding selective inhibitors of clinically relevant carbonic anhydrase (CA) isoforms. The synthesis method involved the production of diazonium salts from 4- and 3-aminobenzenesulfonamide precursors, followed by cyclization and further functionalization to yield structurally diverse pyrazole derivatives. All compounds were evaluated for their inhibitory efficacy against hCA I and II (cytosolic isoforms) and the tumor-associated isoenzymes hCA IX and XII; also, cytotoxicity and molecular modeling studies were conducted for the compounds. The newly synthesized hybrid compounds displayed extensive inhibitory activity, with most derivatives showing significant potency and selectivity for cancer-associated isoforms. More specifically, para-substituted analogs exhibited enhanced inhibitory properties relative to their meta-substituted counterparts. Compound 5f, with a 3,4-dichloro motif, exhibited the highest activity with a very low K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.